Literature DB >> 11080561

The global diabetes model: user friendly version 3.0.

J B Brown1, A Russell, W Chan, K Pedula, M Aickin.   

Abstract

The attributes of Release 3.0 of the user friendly version (UFV) of the global diabetes model (GDM) are described and documented in detail. The GDM is a continuous, stochastic microsimulation model of type 2 diabetes. Suitable for predicting the medical futures of both individuals with diabetes and representative diabetic populations, the GDM predicts medical events (complications of diabetes), survival, utilities, and medical care costs. Incidence rate functions for microvascular and macrovascular complications are based on a combination of published studies and analyses of data describing diabetic members of Kaiser Permanente Northwest Region, a non-profit group-model health maintenance organization. Active risk factors include average blood glucose (HbAlc), systolic blood pressure (SBP), low density lipoprotein cholesterol (LDL), high density lipoprotein cholesterol (HDL), triglycerides, smoking status, and use of prophylactic aspirin. Events predicted include diabetic eye disease, diabetic nephropathy, peripheral neuropathy amputation, myocardial infarction, stroke, peripheral artery disease, congestive heart failure, coronary artery surgery, coronary angioplasty, and death.

Entities:  

Mesh:

Year:  2000        PMID: 11080561     DOI: 10.1016/s0168-8227(00)00215-1

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  34 in total

1.  A guideline for the use of pharmacoeconomic models of diabetes treatment in the US managed-care environment.

Authors:  David L Veenstra; Scott D Ramsey; Sean D Sullivan
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

2.  Insulin pumps: more consultation was needed.

Authors:  Andrew J Palmer; Daniel M D Tucker; Joshua A Ray; William J Valentine; Craig Currie; Phil McEwan; Michael Brändle
Journal:  BMJ       Date:  2005-10-15

Review 3.  A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategies.

Authors:  Adrian Bagust; Marc Evans; Sophie Beale; Philip D Home; Andrew S Perry; Murray Stewart
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 4.  Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.

Authors:  Arran T Shearer; Adrian Bagust; F Javier Ampudia-Blasco; Belén Martínez-Lage Alvarez; Isabel Pérez Escolano; Gonzalo París
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 5.  A Review of Emerging Technologies for the Management of Diabetes Mellitus.

Authors:  Konstantia Zarkogianni; Eleni Litsa; Konstantinos Mitsis; Po-Yen Wu; Chanchala D Kaddi; Chih-Wen Cheng; May D Wang; Konstantina S Nikita
Journal:  IEEE Trans Biomed Eng       Date:  2015-08-19       Impact factor: 4.538

6.  Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada.

Authors:  Douglas Coyle; Andrew J Palmer; Robert Tam
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 7.  The role of models within economic analysis: focus on type 2 diabetes mellitus.

Authors:  Douglas Coyle; Karen M Lee; Bernie J O'Brien
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 8.  Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus.

Authors:  Cornelia B Landersdorfer; William J Jusko
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

9.  Personalized support for chronic conditions. A novel approach for enhancing self-management and improving lifestyle.

Authors:  Irene Lasorsa; Pierluigi D Antrassi; Miloš Ajčević; Kira Stellato; Andrea Di Lenarda; Sara Marceglia; Agostino Accardo
Journal:  Appl Clin Inform       Date:  2016-07-06       Impact factor: 2.342

10.  Impact of a natural disaster on diabetes: exacerbation of disparities and long-term consequences.

Authors:  Vivian A Fonseca; Hayden Smith; Nitesh Kuhadiya; Sharice M Leger; C Lillian Yau; Kristi Reynolds; Lizheng Shi; Roberta H McDuffie; Tina Thethi; Jennifer John-Kalarickal
Journal:  Diabetes Care       Date:  2009-06-19       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.